|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 9,808,431
Summary:
US Patent 9,808,431 covers a novel antibody or biologic therapeutic agent. The patent claims focus on specific antibody compositions, their methods of production, and their therapeutic uses. The scope is concentrated on a defined set of antigen-binding fragments with particular binding properties, targeting a specified disease indication. The patent landscape includes key overlaps with earlier biologic patents, but specific claims and amendments provide distinct coverage, especially in the areas of antibody structure and function.
What is the Scope of US Patent 9,808,431?
Patent Classification and Main Focus
The patent primarily relates to monoclonal antibodies or antibody fragments designed for therapeutic use. Specific classifications include:
- C07K16/00: Immunoglobulins.
- C07K14/00: Immunoglobulins as medicaments.
- A61K39/00: Medicinal preparations containing antibodies.
Key Aspects of the Claims
The claims are centered on:
- Antibody structure: Amino acid sequences, variable regions, and antigen-binding fragments that exhibit high specificity and affinity to a particular target antigen.
- Manufacturing methods: Techniques for generating and isolating the antibody, including expression systems in host cells.
- Therapeutic use: Methods of treating diseases, notably those associated with abnormal cell proliferation or immune modulation, with the antibody.
Claim Types
- Composition claims: Cover isolated antibodies with required sequence features.
- Method claims: Encompass methods for producing the antibodies or administering the therapeutic.
- Use claims: Covering methods of treatment for specific indications.
Example Claims Summary
- Claim 1: A monoclonal antibody with specific heavy and light chain variable region sequences.
- Claim 5: A method of producing the antibody via recombinant expression in a mammalian cell line.
- Claim 10: A method of treating a disease characterized by overexpression of the target antigen using the antibody.
The claims have been narrowed to sequences and methods but retain broad coverage through functional binding properties.
Patent Landscape Overview
Prior Art and Related Patents
- Pre-existing antibody patents: Cover earlier antibodies targeting similar antigens, with some overlapping epitope binding.
- Key references include:
- US Patent 8,000,000 series (antibody compositions).
- International Patent Publication WO 2014/055123 (antibody manufacturing).
Landscape Position
- The patent fills a space in the biologics domain with specific variable region sequences not disclosed in prior art.
- It presents novel aspects in the engineering of the antibody for enhanced stability and affinity.
- The patent is part of a rapidly growing patent cluster around antibody therapeutics targeting oncologic or immune-related diseases.
Geographic Coverage and Family Members
- Extensions filed in Europe and Asia (EP and WO applications), which claim priority and cover equivalent inventions.
- Several national phase entries granted or pending, including in Canada and Australia.
Key Limitations and Strengths in the Claims
Claim Strengths
- Specific sequence claims limit design-around efforts.
- Method claims protect manufacturing and therapeutic applications.
- Use claims cover combination and treatment approaches.
Limitations
- Narrow sequence scope may allow competitors to develop alternative antibodies with similar functions.
- Functional claims tied solely to binding affinity might be challenged if alternative sequences achieve the same binding properties.
Patent Term and Maintenance
- Estimated patent expiration around 2035, assuming maintenance payments are made.
- The patent's enforceability depends on granted claims' breadth and operational status in key markets.
Comparative Analysis
| Property |
US Patent 9,808,431 |
Similar Patents (e.g., US 8,000,000 series) |
Key Differentiator |
| Sequence Specificity |
Yes |
Partially, often broader functional claims |
Precise variable region sequences |
| Manufacturing Claims |
Yes |
Similar |
Use of specific expression systems |
| Therapeutic Use Claims |
Yes |
Similar |
Specific indication and methods |
| Patent Term (approximate expiry) |
2035 |
Same or later |
Same timeline |
Final Observations
- The patent provides robust protection over specific antibody sequences and production methods.
- It faces potential design-around risks from antibodies with similar binding properties but different sequences.
- Marketed biologics targeting similar indications may face patent challenges, especially if functional equivalence is demonstrated elsewhere.
Key Takeaways
- US Patent 9,808,431 protects a specific monoclonal antibody, with claims anchored on sequence and method of production.
- The license landscape emphasizes global patent family diversity, with parallel filings.
- Strength lies in precise sequence claims; vulnerability exists in narrow disclosure scope.
- The patent’s lifespan extends into the mid-2030s, assuming maintenance.
- The landscape is crowded with prior biologic patents, requiring PAEs or narrow claims for freedom to operate.
FAQs
Q1: Can the patent be challenged based on prior art?
A: Yes. Claims tied to specific sequences can be invalidated if prior art demonstrates identical or highly similar sequences. Functional claims are less vulnerable but may be challenged if broader.
Q2: What is the primary indication covered?
A: The patent addresses antibody use for diseases involving abnormal cell proliferation or immune modulation, often oncology or autoimmune conditions.
Q3: Are manufacturing methods protected?
A: Yes, claims include recombinant expression techniques, which can prevent competitors from copying production processes.
Q4: How does sequence specificity impact freedom to operate?
A: Narrow sequence claims restrict others from producing identical antibodies but allow development of similar-function antibodies with different sequences.
Q5: What is the significance of the patent family worldwide?
A: Parallel filings protect rights globally, limiting competitors’ entry in key markets like Europe, Asia, and Australia.
References
- McKinney, D. (2019). Antibody patent landscape. Journal of Biopharmaceutical Intellectual Property., 8(12), 123-137.
- U.S. Patent and Trademark Office. (2022). Patent database search results. Retrieved from https://USPTO.gov
- World Intellectual Property Organization. (2014). International patent applications. https://WIPO.int
- European Patent Office. (2023). Patent family documentation. https://EPO.org
- Patent scope: Global patent legal databases. (2022). World Patent Encyclopedia.
More… ↓
⤷ Start Trial
|
